The European Commission has invested EUR 39.3 million in CEPI, the Coalition for Epidemic Preparedness Innovations, to support the development of broadly protective filovirus vaccines.
55% confidence
HealthInternational
Omissions
The exact amount of EUR 39.3 million does not appear explicitly in any of the sources found; the verification is at topic level (EU/CEPI cooperation on broadly protective filovirus vaccines is real) rather than at amount level.
Other related figures differ: CEPI and the EU's Horizon Europe programme back the Oxford Vaccine Group's multivalent filovirus vaccine research with 'up to $26.7 million' (approximately EUR 24-25 million), and the EU announced a general EUR 73.7 million commitment to CEPI for 2026-2027 — neither matches EUR 39.3 million.
The funding is channelled via the Horizon Europe 'Contribution to CEPI' mechanism (CORDIS programme HORIZON-HLTH-2023-CEPI-11-01-IBA) rather than a direct bilateral EC-CEPI investment, which is a nuance in how the claim is framed.
Source publication dates are post-2024; the CORDIS and CEPI pages were retrievable before the session date but their exact publication dates were not captured in the search snippets.
Sources
PrimaryCORDIS (European Commission project database) — FILOVAX project 101167138Development of Broadly Protective Filovirus Vaccines | FILOVAX — The EU-funded FILOVAX project aims to develop preventive vaccination tools, particularly for high-risk groups like healthcare workers. The idea ...